Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 2
2011 3
2014 1
2016 3
2017 2
2018 4
2020 1
2021 5
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: giordano a. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Autore F, Innocenti I, Reda G, Visentin A, Vitale C, Piciocchi A, Fresa A, Leone MMA, Farina L, Quaresmini G, Baratè C, Giordano A, Ferrari A, Angeletti I, De Paolis MR, Malerba L, Chiurazzi F, Loseto G, Catania G, Sportoletti P, Scortechini I, Moia R, Gentile M, Rigolin GM, Mattiello V, Gattei V, Coscia M, Trentin L, Foà R, Cuneo A, Laurenti L. Autore F, et al. Among authors: giordano a. Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1. Hematol Oncol. 2023. PMID: 37392141
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.
Attolico I, Tarantini F, Carluccio P, Schifone CP, Delia M, Gagliardi VP, Perrone T, Gaudio F, Longo C, Giordano A, Sgherza N, Curci P, Rizzi R, Ricco A, Russo Rossi A, Albano F, Larocca AMV, Vimercati L, Tafuri S, Musto P. Attolico I, et al. Among authors: giordano a. Br J Haematol. 2022 Feb;196(4):928-931. doi: 10.1111/bjh.17873. Epub 2021 Oct 18. Br J Haematol. 2022. PMID: 34664267 Free PMC article. No abstract available.
Primary intracranial dural B cell small lymphocytic lymphoma.
Giordano A, Perrone T, Guarini A, Ciappetta P, Rubini G, Ricco R, Palma M, Specchia G, Liso V. Giordano A, et al. Leuk Lymphoma. 2007 Jul;48(7):1437-43. doi: 10.1080/10428190701387021. Leuk Lymphoma. 2007. PMID: 17613779 Review. No abstract available.
Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link?
Cumbo C, Tarantini F, Zagaria A, Anelli L, Minervini CF, Coccaro N, Tota G, Impera L, Parciante E, Conserva MR, Redavid I, Carluccio P, Delia M, Giordano A, Longo MC, Perrone T, Rossi AR, Specchia G, Musto P, Albano F. Cumbo C, et al. Among authors: giordano a. Front Oncol. 2022 Apr 12;12:873896. doi: 10.3389/fonc.2022.873896. eCollection 2022. Front Oncol. 2022. PMID: 35494055 Free PMC article.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Molica S, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Moia R, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Deodato M, Ielo C, Noto A, Guarente V, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Foa' R, Trentin L, Mauro FR. Molica S, et al. Among authors: giordano a. Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25. Am J Hematol. 2022. PMID: 35170793 Free article. No abstract available.
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, Motta M, Quaglia FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P, Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G, Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatici A, Tisi MC, Stefoni V, Leone M, Baratè C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D, Derenzini E, Levato L, Orsucci L, Penna G, Chiarenza A, Foà R. Cuneo A, et al. Among authors: giordano a. Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13. Hematol Oncol. 2021. PMID: 34258787 Free PMC article. No abstract available.
Risk of lymphoma subtypes by occupational exposure in Southern Italy.
Ferri GM, Specchia G, Mazza P, Ingravallo G, Intranuovo G, Guastadisegno CM, Congedo ML, Lagioia G, Loparco MC, Giordano A, Perrone T, Gaudio F, Spinosa C, Minoia C, D'Onghia L, Strusi M, Corrado V, Cavone D, Vimercati L, Schiavulli N, Cocco P. Ferri GM, et al. Among authors: giordano a. J Occup Med Toxicol. 2017 Nov 23;12:31. doi: 10.1186/s12995-017-0177-2. eCollection 2017. J Occup Med Toxicol. 2017. PMID: 29201133 Free PMC article.
24 results